Drug intelligence / Profile preview

VX-A905

Development stage: Preclinical
Lead developer: VERAXA Biotech
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

VX-A905 is a bispecific antibody-drug conjugate (BsADC) being developed by VERAXA Biotech for the treatment of esophageal cancer and breast cancer. It is part of VERAXA's proprietary BiTAC (Bi-Targeted Antibody Cytotoxicity) platform, which is designed to create next-generation solid tumor therapies with improved tumor targeting and minimized off-target effects by binding to two distinct antigens. The drug is being developed in partnership with OmniAb. As of early 2024, the specific biological targets and cytotoxic payload of VX-A905 have not been publicly disclosed, and the program is in the discovery stage.

Beyond the preview

Go deeper on VX-A905.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VX-A905.

Explore the full profile